npj Vaccines

Papers
(The TQCC of npj Vaccines is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Assessing immunogenicity barriers of the HIV-1 envelope trimer192
Reverse development of vaccines against antimicrobial-resistant pathogens133
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization114
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine114
Risk assessment of retinal vascular occlusion after COVID-19 vaccination111
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants104
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice93
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year93
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity92
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection80
The dengue-specific immune response and antibody identification with machine learning77
Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle73
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern65
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys62
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines62
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine59
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle59
Mapping global public perspectives on mRNA vaccines and therapeutics58
Rational development of a combined mRNA vaccine against COVID-19 and influenza58
PfRH5 vaccine; from the bench to the vial57
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development57
LmCen−/− based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia57
Protein engineering strategies for rational immunogen design57
Immune response against SARS-CoV-2 variants: the role of neutralization assays57
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax55
A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens54
Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination53
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox52
A field test of empathetic refutational and motivational interviewing to address vaccine hesitancy among patients50
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M249
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition49
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen46
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine46
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen46
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex45
Leishmania tarentolae as a platform for the production of vaccines against viral pathogens45
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus45
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth44
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates43
IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development43
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants41
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice41
Antibody responses against influenza A decline with successive years of annual influenza vaccination41
Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins40
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses40
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark40
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum40
Dithranol as novel co-adjuvant for non-invasive dermal vaccination39
Mobilizing domestic support for international vaccine solidarity – recommendations for health crisis communication39
A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N939
A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques37
Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome36
Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types35
Conjugation of HIV-1 envelope to hepatitis B surface antigen alters vaccine responses in rhesus macaques35
Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers34
Vaccination of cattle with the Babesia bovis sexual-stage protein HAP2 abrogates parasite transmission by Rhipicephalus microplus ticks34
Assessing the impact of mRNA vaccination in chronic inflammatory murine model33
Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine33
Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity32
An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets32
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity32
Urgency and necessity of Epstein-Barr virus prophylactic vaccines31
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression30
Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge30
Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery30
Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection30
Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection30
Toxin expression during Staphylococcus aureus infection imprints host immunity to inhibit vaccine efficacy30
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-230
Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome30
Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines29
Strep A: challenges, opportunities, vaccine-based solutions, and economics29
Esoteric beliefs and CAM impact SARS-CoV-2 immunization drivers, uptake and pediatric immunization views in Germany29
Long term T cell response and safety of a tetravalent dengue vaccine in healthy children29
mRNA vaccines induce rapid antibody responses in mice29
An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis29
COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children28
Author Correction: Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization28
Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges28
A broadly protective vaccine against cutaneous human papillomaviruses27
Novel oral adjuvant to enhance cytotoxic memory like NK cell responses in HIV vaccine platform27
The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine26
Engineering the hydroxyl content on aluminum oxyhydroxide nanorod for elucidating the antigen adsorption behavior26
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans26
Analyzing immune responses to varied mRNA and protein vaccine sequences26
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy25
Toxoplasmosis vaccines: what we have and where to go?25
A candidate subunit vaccine induces protective immunity against Mycobacterium avium subspecies paratuberculosis in mice24
The Streptococcus pyogenes vaccine landscape24
A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity24
Modulation of oral vaccine efficacy by the gut microbiota24
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant24
WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV5824
C5aR+ dendritic cells fine-tune the Peyer’s patch microenvironment to induce antigen-specific CD8+ T cells23
Retraction Note: Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies23
Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants23
Continuing development of vaccines and monoclonal antibodies against Zika virus23
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge23
Realising the potential of correlates of protection for vaccine development, licensure and use: short summary23
Establishing an immune correlate of protection for Nipah virus in nonhuman primates23
Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein23
Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma22
Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-1922
Deglycosylation of eukaryotic-expressed flagellin restores adjuvanticity22
COVID-19 and influenza vaccine uptake among pregnant women in national cohorts of England and Wales22
Chimeric hemagglutinin and M2 mRNA vaccine for broad influenza subtype protection22
Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine22
Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation22
Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection22
An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection22
Rapid emergence and transmission of virulence-associated mutations in the oral poliovirus vaccine following vaccination campaigns21
mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response21
Adenovirus type 5-expressing Gn induces better protective immunity than Gc against SFTSV infection in mice21
Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine21
Impact of inactivated vaccine on transmission and evolution of H9N2 avian influenza virus in chickens21
Elicitation of liver-stage immunity by nanoparticle immunogens displaying P. falciparum CSP-derived antigens21
Pre-existing antibodies directed against a tetramerizing domain enhance the immune response against artificially stabilized soluble tetrameric influenza neuraminidase21
Streptococcus pyogenes vaccine candidates do not induce autoimmune responses in a rheumatic heart disease model21
The need for a clinical case definition in test-negative design studies estimating vaccine effectiveness21
A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice21
Live-attenuated ME49Δcdpk3 strain of Toxoplasma gondii protects against acute and chronic toxoplasmosis21
Modified influenza M158–66 peptide vaccination induces non-relevant T-cells and may enhance pathology after challenge20
Is new dengue vaccine efficacy data a relief or cause for concern?20
A highly immunogenic UVC inactivated Sabin based polio vaccine20
Identifying Plasmodium P36 and P52 antigens for coadministration with circumsporozoite protein to enhance vaccine efficacy20
B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs20
Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG20
NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae20
The scientific journey of a novel adjuvant (AS37) from bench to bedside20
Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis20
Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development20
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial20
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses20
Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population20
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen19
HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial19
Genetic ancestry and population structure of vaccinia virus19
Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDTM and COVAXIN® induced immunity in COVID-19 exposed Indians19
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques19
Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants19
Long-term efficacy of an inactivated H5N1 whole-particle influenza vaccine in nonhuman primates18
A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles18
The full health, economic, and social benefits of prospective Strep A vaccination18
Unique features of a recombinant haemagglutinin influenza vaccine that influence vaccine performance18
Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism18
Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein18
A scoping review of global COVID-19 vaccine hesitancy among pregnant persons18
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial18
Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections18
Precocious Eimeria magna transgenically expressing RHDV P2 subdomain induces immune responses in rabbits17
Factors influencing long-term persistence of anti-HBs after hepatitis B vaccination17
Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-217
Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus17
mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice17
Modular assembly and immunological evaluation of a promising bioconjugate nanovaccine against Klebsiella pneumoniae O2 serotype17
Human naïve B cells show evidence of anergy and clonal redemption following vaccination17
Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates17
A broad spectrum Shigella vaccine based on VirG53–353 multiepitope region produced in a cell-free system17
Progress with COVID vaccine development and implementation17
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore17
Author Correction: Selectively targeting haemagglutinin antigen to chicken CD83 receptor induces faster and stronger immunity against avian influenza16
Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort16
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-216
Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model16
Author Correction: Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests16
Vaccine-induced time- and age-dependent mucosal immunity to gastrointestinal parasite infection16
Virus-based vaccine vectors with distinct replication mechanisms differentially infect and activate dendritic cells16
Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles16
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines16
Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination16
Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging16
Author Correction: The dengue-specific immune response and antibody identification with machine learning15
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults15
Optimization of an alum-anchored clinical HIV vaccine candidate15
Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice15
Filovirus vaccines as a response paradigm for emerging infectious diseases15
A centralised immunogen approach to develop a more broadly protective modified live porcine reproductive and respiratory syndrome virus 1 vaccine candidate15
A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine15
Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant15
Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs23015
An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza15
Gut microbiota modulate immune responses to orally and parenterally administered rotavirus in mice15
A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine15
CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines15
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy15
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease15
An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS2114
A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates14
Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers14
A functional enzymatic assay as potential readout for a clinical trial of a schistosomiasis vaccine14
Systems vaccinology identifies immunological correlates of SARS-CoV-2 vaccine response in solid organ transplant recipients14
The immunological interplay between vaccination and the intestinal microbiota14
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice14
Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation study14
The potential global cost-effectiveness of prospective Strep A vaccines and associated implementation efforts14
Impact of mandatory vaccination against serogroup C meningococci in targeted and non-targeted populations in France14
Divergent B-cell repertoire remodelling by mRNA, DNA and live attenuated vaccines in fish14
OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans14
Correlates of immunity to Group A Streptococcus: a pathway to vaccine development14
Author Correction: Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses14
Publisher Correction: Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice14
Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination14
iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA14
Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children14
Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.213
Proteomic approach to identify host cell attachment proteins provides protective Pseudomonas aeruginosa vaccine antigen FtsZ13
Mass cytometry reveals cellular correlates of immune response heterogeneity to SARS-CoV-2 vaccination in the elderly13
Level of antibody to hepatitis B surface antigen declined below 10 mIU/ml is still protective13
A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses13
Affordable SARS-CoV-2 protein vaccines for the pandemic endgame13
A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data13
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development13
Identifying vaccine-hesitant subgroups in the Western Pacific using latent class analysis13
Irradiated whole cell Chlamydia vaccine confers significant protection in a murine genital tract challenge model13
Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland12
A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection12
Japanese encephalitis virus live attenuated vaccine strains display altered immunogenicity, virulence and genetic diversity12
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design12
Author Correction: mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum12
Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease12
A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques12
A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-212
A systems biology approach to define SARS-CoV-2 correlates of protection12
Safety and efficacy of live attenuated PEDV vaccines for neonatal protection12
Potent induction of humoral and cellular immunity after bivalent BA.4/5 mRNA vaccination in dialysis patients12
Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality12
Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens12
Serum antibody profiling identifies vaccine-induced correlates of protection against aerosolized ricin toxin in rhesus macaques12
Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants12
A Plasmodium late liver stage arresting GAP provides superior protection in mice12
A scoping review on the importance of vaccination strategies targeting skin imprinting for arthropod-borne diseases12
Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants12
A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection12
0.031728982925415